Clinical Trial Pre-Screening FAQ: Questions Coordinators Ask
Can clinical trial pre-screening automation reduce repetitive eligibility checks without taking decisions away from coordinators? Yes. It can organize candidate information, compare explicit protocol criteria, identify missing evidence, and route uncertain records for human review before a formal screening visit.
The safest setup treats automation as decision support. A traceable review queue is more useful than a bare eligible or ineligible label, especially when records conflict or a protocol changes.
FAQ: clinical trial pre-screening automation
What does clinical trial pre-screening automation do?
Clinical trial pre-screening automation reviews available participant information against protocol criteria before the full screening visit. A system may extract or organize age, diagnosis, laboratory results, medication history, and other relevant fields, then compare them with configured inclusion and exclusion rules.
It should also show what it could not determine. The governance-first framework described by Huy and colleagues treats eligibility pre-screening as risk-bounded decision support with human oversight and auditability. Pre-screening supports recruitment decisions; it doesn’t replace investigator judgment, informed consent, or formal eligibility assessment.
Which parts of pre-screening can coordinators automate?
Coordinators can automate information gathering, explicit rule checks, missing-data flags, and review-queue creation. Age thresholds and clearly defined laboratory cutoffs usually suit deterministic checks, while symptom interpretation, safety history, and unclear diagnosis wording require qualified review.
For example, a protocol might require an age range, a prior diagnosis, and a recent laboratory result. Automated eligibility screening can confirm the age and diagnosis fields, then mark the laboratory result as missing. It should route the case for follow-up rather than label the candidate eligible. That boundary keeps automated patient eligibility checks from turning incomplete records into false certainty.
Can automation determine whether a participant is eligible?
Automation can support an eligibility assessment, but coordinators and investigators remain responsible for ambiguous or clinically sensitive criteria. A useful output separates four statuses: rule match, probable match, exclusion flag, and insufficient information.
Send borderline cases, conflicting records, and safety-related criteria to qualified staff. For instance, if one record lists a medication that another record omits, the system should flag the conflict. The coordinator reviews the source documents, confirms the current medication list, and records the rationale. That approach follows the human-review and escalation controls proposed in the governance-first automation framework.
How should coordinators check the accuracy of automated pre-screening?
Coordinators should compare every sampled output with the source record, the active protocol version, and the final coordinator decision. Each criterion result should display its source field, evidence date, and status such as confirmed, missing, or contradictory.
During a controlled pilot, track false positives, false negatives, manual overrides, and recurring extraction errors. A practical review record includes:
- the protocol version used;
- the evidence supporting each criterion;
- the reviewer and review date;
- the reason for any override or escalation.
This audit trail for clinical trial automation lets the site investigate an unexpected result instead of asking someone to trust an unexplained score. The governance-first research recommends traceability and ongoing oversight rather than relying on an unsupported accuracy percentage.
What privacy and governance controls does automated pre-screening need?
Automated pre-screening needs data minimization, role-based access, retention rules, vendor review, and documented handling of protected health information. Give the system only the fields needed for the configured protocol checks, and restrict access according to each person’s study responsibilities.
The record should show who reviewed an output, which protocol version applied, and what evidence supported the decision. Confirm the details against institutional policies, study agreements, applicable privacy laws, and sponsor procedures. ICH E6(R3), adopted January 6, 2025, expects participant privacy and data confidentiality to be protected, including in the computerized systems that handle trial data.
How does automation fit into a coordinator’s daily workflow?
Automation fits best between candidate intake and formal screening: receive candidate information, run configured checks, review the evidence, contact the candidate when appropriate, document the outcome, and hand off suitable cases for formal screening.
Keep the queue divided between ready-to-review records and cases blocked by missing information. For example, a possible match arrives with an outdated medication list. The coordinator routes it for confirmation before outreach, then records whether the updated list changes the review status.
How should a site evaluate a pre-screening automation tool?
A site should evaluate clinical trial pre-screening software against its actual review workflow, not a generic feature list. Check whether the tool supports:
- protocol setup and version control;
- visible evidence for every criterion;
- escalation rules for missing or conflicting data;
- review history, permissions, and data export;
- corrections after a protocol amendment.
Test clinical trial automation tools with de-identified or approved historical cases that include clear matches, clear exclusions, missing data, and ambiguous records. No product claim removes the site’s responsibility to validate the workflow.
What is the safest way to introduce clinical trial pre-screening automation?
The safest approach to implementing clinical trial pre-screening automation starts with one defined protocol, a limited set of lower-risk criteria, and a named human reviewer for every output. Set acceptance rules before launch, including evidence traceability, escalation handling, correction workflows, and override documentation.
Map the current clinical trial screening workflow and mark each repetitive check. Then test the system against approved cases before expanding its scope. A protocol amendment can change an exclusion threshold, so the site must confirm that new cases use the current version before reviewing results.
For sites using Rightview's Navigator, it checks a patient record against a study's inclusion and exclusion criteria, with citations, as decision support for the coordinator.